Últimas noticias sobre NewGenIvf Group (NASDAQ:NIVF) Bolsa

NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group Ltd

<p>Evercore ISI Group  analyst Amit Daryanani   maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Outperform and lowers the price target from $145 to $120.</p>


Price Target

Analyst Ratings

DELL

Evercore ISI Group Maintains Outperform on Dell Technologies, Lowers Price Target to $120

<p>Stephens &amp; Co.  analyst Andrew Terrell   reiterates TriCo Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBK#NASDAQ">TCBK</a>) with a Overweight and maintains $47 price target.</p>


Reiteration

TCBK

Stephens & Co. Reiterates Overweight on TriCo Bancshares, Maintains $47 Price Target

<p>Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Royal Caribbean Gr will report an <strong>earnings per share</strong> (EPS) of $2.53.</p>
<p>Investors in Royal Caribbean Gr are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.13, which was followed by a 1.45% increase in the share price the next day.</p>
<p>Here's a look at Royal Caribbean Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.50</td>
<td>5.03</td>
<td>2.75</td>
<td>1.33</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.63</td>
<td>5.20</td>
<td>3.21</td>
<td>1.77</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848957_0.png" alt="eps graph" /></p>
<h3>Tracking Royal Caribbean Gr's Stock Performance</h3>
<p>Shares of Royal Caribbean Gr were trading at $211.97 as of April 25. Over the last 52-week period, shares are up 56.02%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RCL/earnings"><strong>To track all earnings releases for Royal Caribbean Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: Royal Caribbean Gr's Quarterly Earnings

<p>Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Novartis to report an <strong>earnings per share</strong> (EPS) of $2.08.</p>
<p>The market awaits Novartis's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.19 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at Novartis's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.79</td>
<td>1.96</td>
<td>1.86</td>
<td>1.69</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.98</td>
<td>2.06</td>
<td>1.97</td>
<td>1.80</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848950_0.png" alt="eps graph" /></p>
<h3>Novartis Share Price Analysis</h3>
<p>Shares of Novartis were trading at $112.14 as of April 25. Over the last 52-week period, shares are up 15.69%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/NVS/earnings"><strong>To track all earnings releases for Novartis visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For Novartis

<p>BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that BP will report an <strong>earnings per share</strong> (EPS) of $0.69.</p>
<p>The market awaits BP's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company missed EPS by $0.01, which was followed by a 0.38% increase in the share price the next day.</p>
<p>Here's a look at BP's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.45</td>
<td>0.76</td>
<td>0.92</td>
<td>1</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.44</td>
<td>0.83</td>
<td>1</td>
<td>0.97</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848942_0.png" alt="eps graph" /></p>
<h3>BP Share Price Analysis</h3>
<p>Shares of BP were trading at $29.19 as of April 25. Over the last 52-week period, shares are down 24.63%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BP/earnings"><strong>To track all earnings releases for BP visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For BP

<p>Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Hilton Worldwide Holdings will report an <strong>earnings per share</strong> (EPS) of $1.62.</p>
<p>The announcement from Hilton Worldwide Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 0.26% drop in the share price the next day.</p>
<p>Here's a look at Hilton Worldwide Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.68</td>
<td>1.85</td>
<td>1.85</td>
<td>1.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.76</td>
<td>1.92</td>
<td>1.91</td>
<td>1.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>1.0%</td>
<td>1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848931_0.png" alt="eps graph" /></p>
<h3>Hilton Worldwide Holdings Share Price Analysis</h3>
<p>Shares of Hilton Worldwide Holdings were trading at $219.62 as of April 25. Over the last 52-week period, shares are up 13.44%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HLT/earnings"><strong>To track all earnings releases for Hilton Worldwide Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: Hilton Worldwide Holdings's Earnings Preview

<p>Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Sherwin-Williams to report an <strong>earnings per share</strong> (EPS) of $2.18.</p>
<p>Anticipation surrounds Sherwin-Williams's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.03, which was followed by a 2.02% drop in the share price the next day.</p>
<p>Here's a look at Sherwin-Williams's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.06</td>
<td>3.54</td>
<td>3.48</td>
<td>2.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.09</td>
<td>3.37</td>
<td>3.70</td>
<td>2.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-4.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848922_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Sherwin-Williams were trading at $331.62 as of April 25. Over the last 52-week period, shares are up 11.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Sherwin-Williams</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Sherwin-Williams.</p>
<p>Analysts have provided Sherwin-Williams with 11 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $387.09, suggesting a potential 16.73% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Ecolab, DuPont de Nemours and PPG Indus, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Ecolab, with an average 1-year price target of $285.71, suggesting a potential 13.84% downside.</li>
<li>Analysts currently favor an Outperform trajectory for DuPont de Nemours, with an average 1-year price target of $87.38, suggesting a potential 73.65% downside.</li>
<li>Analysts currently favor an Neutral trajectory for PPG Indus, with an average 1-year price target of $125.45, suggesting a potential 62.17% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Ecolab, DuPont de Nemours and PPG Indus, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sherwin-Williams</td>
<td>Neutral</td>
<td>0.86%</td>
<td>$2.57B</td>
<td>11.70%</td>
</tr>
<tr>
<td>Ecolab</td>
<td>Outperform</td>
<td>1.70%</td>
<td>$1.74B</td>
<td>5.47%</td>
</tr>
<tr>
<td>DuPont de Nemours</td>
<td>Outperform</td>
<td>6.69%</td>
<td>$1.12B</td>
<td>-0.50%</td>
</tr>
<tr>
<td>PPG Indus</td>
<td>Neutral</td>
<td>-7.72%</td>
<td>$755M</td>
<td>-3.84%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Sherwin-Williams ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks lower for Return on Equity. Overall, Sherwin-Williams is positioned favorably compared to its peers in terms of financial performance metrics.</p>
<h3>About Sherwin-Williams</h3>
<p>Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 5,000 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.</p>
<h3>Financial Insights: Sherwin-Williams</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Sherwin-Williams's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>0.86%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Sherwin-Williams's net margin is impressive, surpassing industry averages. With a net margin of <strong>9.06%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sherwin-Williams's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>11.7%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Sherwin-Williams's ROA excels beyond industry benchmarks, reaching <strong>2.02%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.94</strong>, Sherwin-Williams faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/SHW/earnings"><strong>To track all earnings releases for Sherwin-Williams visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Sherwin-Williams's Upcoming Earnings

<p>Wells Fargo  analyst Finian O'Shea   maintains FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) with a Underweight and lowers the price target from $19 to $18.</p>


Wells Fargo Maintains Underweight on FS KKR Capital, Lowers Price Target to $18

<p>Evercore ISI Group  analyst Amit Daryanani   maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Outperform and lowers the price target from $75 to $67.</p>


CSCO

Evercore ISI Group Maintains Outperform on Cisco Systems, Lowers Price Target to $67

<p>Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Altria Group to report an <strong>earnings per share</strong> (EPS) of $1.19.</p>
<p>Investors in Altria Group are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.01 in the last quarter, leading to a 1.34% increase in the share price on the following day.</p>
<p>Here's a look at Altria Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.28</td>
<td>1.35</td>
<td>1.34</td>
<td>1.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.29</td>
<td>1.38</td>
<td>1.31</td>
<td>1.15</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848912_0.png" alt="eps graph" /></p>
<h3>Tracking Altria Group's Stock Performance</h3>
<p>Shares of Altria Group were trading at $58.26 as of April 25. Over the last 52-week period, shares are up 33.51%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MO/earnings"><strong>To track all earnings releases for Altria Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Altria Group's Earnings Outlook

<p>S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect S&amp;P Global to report an <strong>earnings per share</strong> (EPS) of $4.24.</p>
<p>The announcement from S&amp;P Global is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.30, leading to a 1.67% drop in the share price the following trading session.</p>
<p>Here's a look at S&amp;P Global's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.47</td>
<td>3.64</td>
<td>3.54</td>
<td>3.66</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.77</td>
<td>3.89</td>
<td>4.04</td>
<td>4.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848905_0.png" alt="eps graph" /></p>
<h3>S&amp;P Global Share Price Analysis</h3>
<p>Shares of S&amp;P Global were trading at $480.0 as of April 25. Over the last 52-week period, shares are up 15.91%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analysts' Take on S&amp;P Global</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on S&amp;P Global.</p>
<p>The consensus rating for S&amp;P Global is Outperform, based on 8 analyst ratings. With an average one-year price target of $605.25, there's a potential 26.09% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of CME Group, Intercontinental Exchange and Moodys, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for CME Group, with an average 1-year price target of $266.18, suggesting a potential 44.55% downside.</li>
<li>Analysts currently favor an Buy trajectory for Intercontinental Exchange, with an average 1-year price target of $200.0, suggesting a potential 58.33% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Moodys, with an average 1-year price target of $513.82, suggesting a potential 7.05% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for CME Group, Intercontinental Exchange and Moodys are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>S&amp;P Global</td>
<td>Outperform</td>
<td>13.96%</td>
<td>$2.48B</td>
<td>2.62%</td>
</tr>
<tr>
<td>CME Group</td>
<td>Neutral</td>
<td>7.67%</td>
<td>$1.30B</td>
<td>3.53%</td>
</tr>
<tr>
<td>Intercontinental Exchange</td>
<td>Buy</td>
<td>13.65%</td>
<td>$1.62B</td>
<td>2.54%</td>
</tr>
<tr>
<td>Moodys</td>
<td>Neutral</td>
<td>7.73%</td>
<td>$1.43B</td>
<td>17.21%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>S&amp;P Global ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, S&amp;P Global is positioned well compared to its peers in terms of financial performance metrics.</p>
<h3>Unveiling the Story Behind S&amp;P Global</h3>
<p>S&amp;P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&amp;P's largest segment by profitability. S&amp;P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&amp;P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.</p>
<h3>S&amp;P Global: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> S&amp;P Global displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>13.96%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> S&amp;P Global's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>24.5%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> S&amp;P Global's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.62%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.46%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> S&amp;P Global's debt-to-equity ratio is below the industry average. With a ratio of <b>0.36</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/SPGI/earnings"><strong>To track all earnings releases for S&amp;P Global visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SPGI

Earnings Preview: S&P Global

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Advanced Micro Devices</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Advanced Micro Devices.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 26% bullish and 53%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $429,598, and 8 are calls, for a total amount of $1,198,255.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $145.0 for Advanced Micro Devices over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Advanced Micro Devices's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Advanced Micro Devices's substantial trades, within a strike price spectrum from $90.0 to $145.0 over the preceding 30 days.</p>
<h3>Advanced Micro Devices Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848900_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$3.65</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$95.00</td>
<td>$942.7K</td>
<td>4.4K</td>
<td align="right">627</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$16.35</td>
<td>$16.25</td>
<td>$16.34</td>
<td>$110.00</td>
<td>$104.4K</td>
<td>24.6K</td>
<td align="right">64</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$7.75</td>
<td>$7.65</td>
<td>$7.67</td>
<td>$100.00</td>
<td>$90.8K</td>
<td>23.9K</td>
<td align="right">346</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$15.65</td>
<td>$15.55</td>
<td>$15.62</td>
<td>$110.00</td>
<td>$60.9K</td>
<td>24.6K</td>
<td align="right">191</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.7</td>
<td>$7.65</td>
<td>$7.72</td>
<td>$100.00</td>
<td>$58.5K</td>
<td>23.9K</td>
<td align="right">145</td>
</tr>
</tbody>
</table>
</p>
<h3>About Advanced Micro Devices</h3>
<p>Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.</p>
<p>In light of the recent options history for Advanced Micro Devices, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Advanced Micro Devices</h3>
<ul>
<li>Currently trading with a volume of 3,010,677, the AMD's price is up by 0.73%, now at $97.35. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 8 days.</li>
</ul>
<h3>Professional Analyst Ratings for Advanced Micro Devices</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $121.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Wedbush keeps a Outperform rating on Advanced Micro Devices with a target price of $115.<br />
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on Advanced Micro Devices with a target price of $135.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Advanced Micro Devices, targeting a price of $110.<br />
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Advanced Micro Devices with a target price of $126.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Advanced Micro Devices with a target price of $120. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Advanced Micro Devices, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

What the Options Market Tells Us About Advanced Micro Devices

<p>Deep-pocketed investors have adopted a bullish approach towards Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GOOGL usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Alphabet. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 70% leaning bullish and 30% bearish. Among these notable options, 2 are puts, totaling $65,400, and 8 are calls, amounting to $386,202.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $190.0 for Alphabet, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Alphabet's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Alphabet's significant trades, within a strike price range of $155.0 to $190.0, over the past month.</p>
<h3>Alphabet Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848895_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GOOGL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.3</td>
<td>$6.25</td>
<td>$6.3</td>
<td>$170.00</td>
<td>$92.6K</td>
<td>8.0K</td>
<td align="right">210</td>
</tr>
<tr>
<td>GOOGL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$14.9</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$170.00</td>
<td>$59.2K</td>
<td>7.5K</td>
<td align="right">0</td>
</tr>
<tr>
<td>GOOGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.6</td>
<td>$4.55</td>
<td>$4.6</td>
<td>$170.00</td>
<td>$53.2K</td>
<td>20.6K</td>
<td align="right">120</td>
</tr>
<tr>
<td>GOOGL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.35</td>
<td>$170.00</td>
<td>$40.0K</td>
<td>8.0K</td>
<td align="right">0</td>
</tr>
<tr>
<td>GOOGL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.85</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$160.00</td>
<td>$39.2K</td>
<td>10.9K</td>
<td align="right">174</td>
</tr>
</tbody>
</table>
</p>
<h3>About Alphabet</h3>
<p>Alphabet is a holding company that wholly owns internet giant Google. The California-based company derives slightly less than 90% of its revenue from Google services, the vast majority of which is advertising sales. Alongside online ads, Google services houses sales stemming from Google's subscription services (YouTube TV, YouTube Music among others), platforms (sales and in-app purchases on Play Store), and devices (Chromebooks, Pixel smartphones, and smart home products such as Chromecast). Google's cloud computing platform, or GCP, accounts for roughly 10% of Alphabet's revenue with the firm's investments in up-and-coming technologies such as self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) making up the rest.</p>
<p>In light of the recent options history for Alphabet, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Alphabet</h3>
<ul>
<li>With a trading volume of 4,323,557, the price of GOOGL is down by -0.12%, reaching $161.77.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 85 days from now.</li>
</ul>
<h3>Expert Opinions on Alphabet</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $189.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Rosenblatt has decided to maintain their Neutral rating on Alphabet, which currently sits at a price target of $189.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Alphabet, targeting a price of $185.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Alphabet with a target price of $195.<br />
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on Alphabet, which currently sits at a price target of $200.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $178. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Alphabet, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


GOOGL

Alphabet's Options: A Look at What the Big Money is Thinking

<p>Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Visa will report an <strong>earnings per share</strong> (EPS) of $2.68.</p>
<p>The market awaits Visa's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.09, leading to a 0.36% drop in the share price on the subsequent day.</p>
<p>Here's a look at Visa's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.66</td>
<td>2.58</td>
<td>2.42</td>
<td>2.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.75</td>
<td>2.71</td>
<td>2.42</td>
<td>2.51</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>3.0%</td>
<td>-4.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848893_0.png" alt="eps graph" /></p>
<h3>Market Performance of Visa's Stock</h3>
<p>Shares of Visa were trading at $335.17 as of April 25. Over the last 52-week period, shares are up 26.27%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Visa</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Visa.</p>
<p>Analysts have provided Visa with 16 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $383.5, suggesting a potential 14.42% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Mastercard, Fiserv and PayPal Holdings, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Mastercard, with an average 1-year price target of $640.6, suggesting a potential 91.13% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Fiserv, with an average 1-year price target of $256.5, suggesting a potential 23.47% downside.</li>
<li>Analysts currently favor an Neutral trajectory for PayPal Holdings, with an average 1-year price target of $84.13, suggesting a potential 74.9% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Mastercard, Fiserv and PayPal Holdings are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa</td>
<td>Outperform</td>
<td>10.15%</td>
<td>$7.49B</td>
<td>13.56%</td>
</tr>
<tr>
<td>Mastercard</td>
<td>Outperform</td>
<td>14.37%</td>
<td>$5.84B</td>
<td>48.00%</td>
</tr>
<tr>
<td>Fiserv</td>
<td>Outperform</td>
<td>-2.30%</td>
<td>$3.23B</td>
<td>3.21%</td>
</tr>
<tr>
<td>PayPal Holdings</td>
<td>Neutral</td>
<td>4.24%</td>
<td>$3.94B</td>
<td>5.52%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Visa ranks at the top for Gross Profit and Revenue Growth among its peers. It is in the middle for Return on Equity. The company with the highest Return on Equity has the lowest Revenue Growth. The company with the lowest Gross Profit has a negative Revenue Growth.</p>
<h3>All You Need to Know About Visa</h3>
<p>Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.</p>
<h3>Understanding the Numbers: Visa's Finances</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Visa displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.15%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Visa's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>53.83%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Visa's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>13.56%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Visa's ROA excels beyond industry benchmarks, reaching <strong>5.49%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.55</strong>, Visa adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/V/earnings"><strong>To track all earnings releases for Visa visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Visa

<p>Financial giants have made a conspicuous bullish move on Palantir Technologies. Our analysis of options history for Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) revealed 24 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 29% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $603,050, and 12 were calls, valued at $791,997.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $95.0 and $185.0 for Palantir Technologies, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Palantir Technologies's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Palantir Technologies's significant trades, within a strike price range of $95.0 to $185.0, over the past month.</p>
<h3>Palantir Technologies Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848890_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/02/25</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.57</td>
<td>$115.00</td>
<td>$184.5K</td>
<td>16.0K</td>
<td>625</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$12.6</td>
<td>$12.35</td>
<td>$12.35</td>
<td>$110.00</td>
<td>$127.9K</td>
<td>17.0K</td>
<td>816</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$12.05</td>
<td>$11.75</td>
<td>$11.98</td>
<td>$110.00</td>
<td>$91.0K</td>
<td>17.0K</td>
<td>135</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$16.0</td>
<td>$15.65</td>
<td>$16.0</td>
<td>$102.00</td>
<td>$83.2K</td>
<td>685</td>
<td>57</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$8.3</td>
<td>$8.15</td>
<td>$8.22</td>
<td>$110.00</td>
<td>$78.9K</td>
<td>3.6K</td>
<td>3.9K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palantir Technologies</h3>
<p>Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.</p>
<h3>Where Is Palantir Technologies Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 14,529,718, with PLTR's price up by 0.78%, positioned at $113.66.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Expert Opinions on Palantir Technologies</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $95.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from DA Davidson keeps a Neutral rating on Palantir Technologies with a target price of $100.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Palantir Technologies, which currently sits at a price target of $90. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Palantir Technologies, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PLTR

Smart Money Is Betting Big In PLTR Options

<p>Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Honeywell Intl will report an <strong>earnings per share</strong> (EPS) of $2.21.</p>
<p>Anticipation surrounds Honeywell Intl's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.15, leading to a 2.05% drop in the share price on the subsequent day.</p>
<p>Here's a look at Honeywell Intl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.32</td>
<td>2.50</td>
<td>2.42</td>
<td>2.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.47</td>
<td>2.58</td>
<td>2.49</td>
<td>2.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848884_0.png" alt="eps graph" /></p>
<h3>Tracking Honeywell Intl's Stock Performance</h3>
<p>Shares of Honeywell Intl were trading at $199.16 as of April 25. Over the last 52-week period, shares are up 4.55%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analysts' Take on Honeywell Intl</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Honeywell Intl.</p>
<p>Honeywell Intl has received a total of 8 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $229.75, the consensus suggests a potential 15.36% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and 3M, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for 3M, with an average 1-year price target of $140.14, suggesting a potential 29.63% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>In the peer analysis summary, key metrics for  and 3M are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Honeywell Intl</td>
<td>Neutral</td>
<td>6.86%</td>
<td>$3.67B</td>
<td>7.13%</td>
</tr>
<tr>
<td>3M</td>
<td>Outperform</td>
<td>-1.03%</td>
<td>$2.48B</td>
<td>26.87%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Honeywell Intl ranks higher than its peers in terms of Revenue Growth and Gross Profit, indicating stronger performance in these areas. However, it lags behind in terms of Return on Equity. Overall, Honeywell Intl is positioned towards the top compared to its peers based on the provided metrics.</p>
<h3>Discovering Honeywell Intl: A Closer Look</h3>
<p>Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.</p>
<h3>A Deep Dive into Honeywell Intl's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Honeywell Intl displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>6.86%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Honeywell Intl's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>12.74%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Honeywell Intl's ROE excels beyond industry benchmarks, reaching <strong>7.13%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.73%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.73</strong>.</p>
<p><a href="https://www.benzinga.com/quote/HON/earnings"><strong>To track all earnings releases for Honeywell Intl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Honeywell Intl's Earnings Forecast

<p>Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Charter Communications, revealing an average target of $400.71, a high estimate of $450.00, and a low estimate of $320.00. Marking an increase of 3.86%, the current average surpasses the previous average price target of $385.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848881_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Charter Communications among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Alan Gould          &#x7C;Loop Capital        &#x7C;Raises         &#x7C;Hold           &#x7C;             $430.00&#x7C;$385.00             &#x7C;<br />
&#x7C;Benjamin Swinburne  &#x7C;Morgan Stanley      &#x7C;Raises         &#x7C;Equal-Weight   &#x7C;             $415.00&#x7C;$385.00             &#x7C;<br />
&#x7C;Steven Cahall       &#x7C;Wells Fargo         &#x7C;Lowers         &#x7C;Equal-Weight   &#x7C;             $380.00&#x7C;$400.00             &#x7C;<br />
&#x7C;Michael Rollins     &#x7C;Citigroup           &#x7C;Announces      &#x7C;Buy            &#x7C;             $425.00&#x7C;-                   &#x7C;<br />
&#x7C;Kannan Venkateshwar &#x7C;Barclays            &#x7C;Raises         &#x7C;Underweight    &#x7C;             $320.00&#x7C;$315.00             &#x7C;<br />
&#x7C;Jonathan Atkin      &#x7C;RBC Capital         &#x7C;Raises         &#x7C;Sector Perform &#x7C;             $385.00&#x7C;$380.00             &#x7C;<br />
&#x7C;Matthew Harrigan    &#x7C;Benchmark           &#x7C;Maintains      &#x7C;Buy            &#x7C;             $450.00&#x7C;$450.00             &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Charter Communications. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charter Communications compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Charter Communications's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Charter Communications's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CHTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Charter Communications analyst ratings.</strong></a></p>
<h2>All You Need to Know About Charter Communications</h2>
<p>Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 57 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.</p>
<h3>Breaking Down Charter Communications's Financial Performance</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Charter Communications's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>1.57%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Charter Communications's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.53%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Charter Communications's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.88%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.98%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Charter Communications's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>6.14</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CHTR

What 7 Analyst Ratings Have To Say About Charter Communications

<p>Wells Fargo  analyst Finian O'Shea   maintains Crescent Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCAP#NASDAQ">CCAP</a>) with a Equal-Weight and lowers the price target from $18 to $16.</p>


CCAP

Wells Fargo Maintains Equal-Weight on Crescent Capital BDC, Lowers Price Target to $16

<p>Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Regeneron Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $9.22.</p>
<p>Anticipation surrounds Regeneron Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.88 in the last quarter, leading to a 2.82% increase in the share price on the following day.</p>
<p>Here's a look at Regeneron Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>11.19</td>
<td>11.69</td>
<td>10.53</td>
<td>10.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>12.07</td>
<td>12.46</td>
<td>11.56</td>
<td>9.55</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848875_0.png" alt="eps graph" /></p>
<h3>Performance of Regeneron Pharmaceuticals Shares</h3>
<p>Shares of Regeneron Pharmaceuticals were trading at $602.64 as of April 25. Over the last 52-week period, shares are down 31.6%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Observations about Regeneron Pharmaceuticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Regeneron Pharmaceuticals.</p>
<p>Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of argenx and Alnylam Pharmaceuticals, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for argenx, with an average 1-year price target of $755.64, suggesting a potential 25.39% upside.</li>
<li>Analysts currently favor an Buy trajectory for Alnylam Pharmaceuticals, with an average 1-year price target of $342.15, suggesting a potential 43.22% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary presents essential metrics for argenx and Alnylam Pharmaceuticals, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>Buy</td>
<td>10.33%</td>
<td>$3.22B</td>
<td>3.13%</td>
</tr>
<tr>
<td>argenx</td>
<td>Buy</td>
<td>81.50%</td>
<td>$665.75M</td>
<td>14.08%</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>Buy</td>
<td>34.90%</td>
<td>$490.35M</td>
<td>-168.47%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Regeneron Pharmaceuticals ranks highest in Gross Profit among its peers. It is in the middle for Revenue Growth and Return on Equity.</p>
<h3>All You Need to Know About Regeneron Pharmaceuticals</h3>
<p>Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<h3>Financial Milestones: Regeneron Pharmaceuticals's Journey</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Regeneron Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>10.33%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>24.22%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Regeneron Pharmaceuticals's ROE excels beyond industry benchmarks, reaching <strong>3.13%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.44%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.09</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/REGN/earnings"><strong>To track all earnings releases for Regeneron Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


REGN

Insights into Regeneron Pharmaceuticals's Upcoming Earnings

<p>4 analysts have shared their evaluations of Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $72.25, a high estimate of $84.00, and a low estimate of $64.00. A decline of 1.37% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745848869_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Centene. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Andrew Mok          &#x7C;Barclays            &#x7C;Lowers         &#x7C;Overweight     &#x7C;              $84.00&#x7C;$93.00              &#x7C;<br />
&#x7C;Michael Ha          &#x7C;Baird               &#x7C;Lowers         &#x7C;Neutral        &#x7C;              $69.00&#x7C;$71.00              &#x7C;<br />
&#x7C;David Windley       &#x7C;Jefferies           &#x7C;Raises         &#x7C;Hold           &#x7C;              $64.00&#x7C;$53.00              &#x7C;<br />
&#x7C;Stephen Baxter      &#x7C;Wells Fargo         &#x7C;Lowers         &#x7C;Overweight     &#x7C;              $72.00&#x7C;$76.00              &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Centene. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Centene compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Centene's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Centene's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Centene analyst ratings.</strong></a></p>
<h2>Get to Know Centene Better</h2>
<p>Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.</p>
<h3>Centene's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Centene's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>3.41%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>0.69%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Centene's ROE excels beyond industry benchmarks, reaching <strong>1.05%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Centene's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.34%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.74</strong>, Centene adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 4 Analyst Projections For Centene

Health Care

Press Releases

NewGen Announces Strategic Acquisition of MicroSort Reproductive Technology

NewGen Announces Reverse Stock Split

Management

NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

NewGen Issues Clarification on Press Release Titled "NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director" dated February 20, 2025

NewGen Regains Compliance with Nasdaq Minimum Bid Price Requirement and Announces Listing Transfer to the Nasdaq Capital Market

NewGen and BOBCARE Announce Strategic Collaboration to Expand Fertility Services in Kyrgyzstan

NewGenIvf Provides Update on Proposed Reverse Merger with European Wellness Holdings and Completion of Strategic Acquisition of MicroSort Reproductive Technology

NewGenIVF Announces Termination of Proposed Reverse Merger Transaction with European Wellness

Financing

General

NewGen Secures Strategic Funding to Drive International Expansion and Corporate Growth

NewGen Filed 2024 Annual Report on Form 20-F

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Kindly MD

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Comments

NewGenIvf Group

Noticias

Últimas noticias sobre NewGenIvf Group (NASDAQ:NIVF) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL